Bray Capital Advisors Sells 178 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Bray Capital Advisors lessened its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 0.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 18,991 shares of the financial services provider’s stock after selling 178 shares during the quarter. Bray Capital Advisors’ holdings in iShares Biotechnology ETF were worth $2,765,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Highline Wealth Partners LLC bought a new stake in shares of iShares Biotechnology ETF in the 3rd quarter worth approximately $30,000. Bbjs Financial Advisors LLC bought a new stake in iShares Biotechnology ETF during the 2nd quarter valued at $31,000. Voisard Asset Management Group Inc. bought a new stake in iShares Biotechnology ETF during the 3rd quarter valued at $59,000. Eastern Bank bought a new stake in iShares Biotechnology ETF during the 3rd quarter valued at $65,000. Finally, Chris Bulman Inc bought a new stake in iShares Biotechnology ETF during the 2nd quarter valued at $64,000. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

Shares of IBB stock opened at $148.85 on Friday. The company’s fifty day simple moving average is $144.84 and its two-hundred day simple moving average is $141.09. iShares Biotechnology ETF has a 1 year low of $113.56 and a 1 year high of $150.57.

iShares Biotechnology ETF Dividend Announcement

The firm also recently announced a dividend, which was paid on Monday, September 30th. Shareholders of record on Wednesday, September 25th were issued a dividend of $0.2005 per share. The ex-dividend date was Wednesday, September 25th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.